Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
GSK prices $280,336,000 Senior Notes Due 2023 Exchangeable into Theravance Biopharma Ordinary Shares
-
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
GSK announces Proposed Unregistered Offering of Senior Notes Exchangeable into Theravance Biopharma Ordinary Shares
-
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
-
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir.
-
GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
16 presentations, including new analyses from the pivotal DREAMM-2 study and initial results from the DREAMM-4 study
-
GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations
Announcement follows completion of global manufacturing review and decision to invest in expanded manufacturing capacity
-
DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
13-month update on the DREAMM-2 study shows median overall survival of 13.7 months and median duration of response of 11 months
-
FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
An approval would give Nucala a third indication in an eosinophil-driven disease
-
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
Samsung Biologics will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing.
-
GSK highlights scientific innovation and advances in its growing oncology portfolio at ASCO 2020
26 abstracts across 8 tumour types, advancing GSK’s goal of maximising outcomes for patients
-
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP
Interim analysis of the HIV Prevention Trials Network (HPTN) 083 study.
-
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
Zejula is the only oral monotherapy available as first-line maintenance treatment for women regardless of BRCA mutational status
-
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
GSK delivers strong Q1: sales £9.1 billion +19% AER, +19% CER (Proforma +10% CER*)
-
GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer
Data accepted as a late-breaking abstract and presented as a webinar as part of the Society of Gynecologic Oncology 2020 virtual congress
-
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine.
-
GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks.
-
FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of biomarker status
Zejula is the only monotherapy available for women who do not have a BRCA mutation.
-
Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
Pivotal data support regulatory filing for additional eosinophil-driven disease
-
GSK completes divestment of Horlicks and other Consumer Healthcare nutrition products in India and certain other markets
GSK today announced the completion of its divestment of Horlicks and other Consumer Healthcare nutrition products in India to Unilever.
-
Zejula (niraparib) is the first and only once-daily PARP inhibitor FDA-approved as a first-line monotherapy maintenance treatment for women with advanced ovarian cancer regardless of biomarker status
GlaxoSmithKline plc today announced the U.S. FDA approved the company’s supplemental New Drug Application (sNDA) of Zejula (niraparib).